Shilpa Shetty Kundra leads Tracxn’s ranking of celebrity startup investors with 10 disclosed funding rounds between 2021 and 2026 YTD. MS D...

Mumbai-based B2B pharma distribution platform Fundly.ai has raised $4 million from existing investors Accel and Multiply, along with ventur...

The Symbiotec Pharmalab IPO plans to channel Rs 112.50 crore towards the prepayment and/or repayment, fully or partially, of select outstan...

Symbiotec Pharmalab's IPO saw strong investor demand, closing oversubscribed 71.26 times. The company aimed to raise Rs 1,757 crore through...

India's plant-based protein ingredient market is set to double to Rs 9,000 crore within five years. Consumers are shifting towards targeted...

Symbiotec Pharmalab's IPO saw robust investor demand, with the issue subscribed 1.85 times. The company aims to raise Rs 1,757 crore throug...

Happy Wednesday! AMI has ordered 9,000 Nvidia Vera Rubin chips, becoming one of Asia’s first such adopters. This and more in today’s ETtech...

Honasa Consumer has called off its planned acquisition of a 58% stake in nutraceuticals brand Fluence Pharma due to unmet closing condition...

A high-level committee will examine establishing a National Sanjeevani Research Centre for Sea Buckthorn. This initiative aims to position ...

Symbiotec Pharmalab IPO GMP: Symbiotec Pharmalab’s Rs 1,757 crore IPO opened August 24, with a Rs 938–988 price band and 41% grey-market pr...

Shares of Kronox Lab Sciences surged after Indo Borax and Zenrock Chemicals announced plans to acquire a 64.26% stake in the company and la...

Symbiotec Pharmalab will launch its ₹1,757-crore IPO from August 24–27, 2026, with a price band of ₹938–988 per share. The minimum bid is 1...

The Reserve Bank of India is prematurely closing a special window for FCNR(B) bank deposits from the Indian diaspora, originally set to end...

For the chemicals sector, it all depends on a transformation that is still unfolding and will take years to play out. Backward-integration ...

The Indian supplements market is anticipated to soar to nearly fifty-seven billion dollars by twenty thirty, driven by heightened consumer ...

For Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...

Will be 4th acquisition for the US private equity giant in India’s healthsector in four months. Kedaara to make 5x rupee returns on exit.